FM
SPRY icon

Frazier Management’s ARS Pharmaceuticals SPRY Stock Holding History

Frazier Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-35,750
Closed -$1.66M – 39
2020
Q4 		$1.66M Buy
+35,750
New +$1.19M 0.13% 32

Other funds holding SPRY

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Frazier Management's SPRY Position: Q1 2021 in Review

Frazier Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2021, closing a stake of 35,750 shares — an estimated $1.66M sold.

Frazier Management first reported a position in SPRY in Q4 2020 and held it in 1 quarter. The position peaked at $1.66M in Q4 2020. 68 funds tracked by Wall St. Rank hold SPRY as of Q1 2021.

  • Frazier Management reported no remaining ARS Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Frazier Management sold 35,750 ARS Pharmaceuticals shares in Q1 2021, an estimated $1.66M.
  • Frazier Management first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Frazier Management's ARS Pharmaceuticals position peaked at $1.66M in Q4 2020.
  • 68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2021.

Based on Frazier Management's 13F filing for Q1 2021, filed 12 May 2021.